Our findings implicating Moesin dysregulation in Alzheimer’s disease and related tauopathy converge with those of the National Institute on Aging’s Accelerating Medicines Partnership – Alzheimer’s Disease consortium, who have nominated Moesin as a drug target for Alzheimer’s disease (https://agora.ampadportal.org/genes/genes-router:gene-details/ENSG00000147065) based on genomic and proteomic data from human Alzheimer’s disease samples. The gene discussed is MSN; the disease is tauopathy.